Literature DB >> 26383952

Dengue viruses cluster antigenically but not as discrete serotypes.

Leah C Katzelnick1, Judith M Fonville2, Gregory D Gromowski3, Jose Bustos Arriaga3, Angela Green4, Sarah L James5, Louis Lau4, Magelda Montoya4, Chunling Wang4, Laura A VanBlargan3, Colin A Russell6, Hlaing Myat Thu7, Theodore C Pierson3, Philippe Buchy8, John G Aaskov9, Jorge L Muñoz-Jordán10, Nikos Vasilakis11, Robert V Gibbons12, Robert B Tesh11, Albert D M E Osterhaus13, Ron A M Fouchier13, Anna Durbin14, Cameron P Simmons15, Edward C Holmes16, Eva Harris4, Stephen S Whitehead3, Derek J Smith17.   

Abstract

The four genetically divergent dengue virus (DENV) types are traditionally classified as serotypes. Antigenic and genetic differences among the DENV types influence disease outcome, vaccine-induced protection, epidemic magnitude, and viral evolution. We characterized antigenic diversity in the DENV types by antigenic maps constructed from neutralizing antibody titers obtained from African green monkeys and after human vaccination and natural infections. Genetically, geographically, and temporally, diverse DENV isolates clustered loosely by type, but we found that many are as similar antigenically to a virus of a different type as to some viruses of the same type. Primary infection antisera did not neutralize all viruses of the same DENV type any better than other types did up to 2 years after infection and did not show improved neutralization to homologous type isolates. That the canonical DENV types are not antigenically homogeneous has implications for vaccination and research on the dynamics of immunity, disease, and the evolution of DENV.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26383952      PMCID: PMC4876809          DOI: 10.1126/science.aac5017

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  62 in total

1.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok.

Authors:  B Adams; E C Holmes; C Zhang; M P Mammen; S Nimmannitya; S Kalayanarooj; M Boots
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

3.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

4.  Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Authors:  Anna P Durbin; Sandra V Mayer; Shannan L Rossi; Irma Y Amaya-Larios; Jose Ramos-Castaneda; Eng Eong Ooi; M Jane Cardosa; Jorge L Munoz-Jordan; Robert B Tesh; William B Messer; Scott C Weaver; Nikos Vasilakis
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616

5.  Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever.

Authors:  Tadeusz J Kochel; Douglas M Watts; Scott B Halstead; Curtis G Hayes; Angelica Espinoza; Vidal Felices; Roxana Caceda; Christian T Bautista; Ysabel Montoya; Susan Douglas; Kevin L Russell
Journal:  Lancet       Date:  2002-07-27       Impact factor: 79.321

6.  Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Authors:  Stephen J Thomas; Ananda Nisalak; Kathryn B Anderson; Daniel H Libraty; Siripen Kalayanarooj; David W Vaughn; Robert Putnak; Robert V Gibbons; Richard Jarman; Timothy P Endy
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

7.  Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence.

Authors:  E A Henchal; M K Gentry; J M McCown; W E Brandt
Journal:  Am J Trop Med Hyg       Date:  1982-07       Impact factor: 2.345

8.  Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.

Authors:  Timothy P Endy; Ananda Nisalak; Supamit Chunsuttitwat; David W Vaughn; Sharone Green; Francis A Ennis; Alan L Rothman; Daniel H Libraty
Journal:  J Infect Dis       Date:  2004-03-01       Impact factor: 5.226

9.  Antibody landscapes after influenza virus infection or vaccination.

Authors:  J M Fonville; S H Wilks; S L James; A Fox; M Ventresca; M Aban; L Xue; T C Jones; N M H Le; Q T Pham; N D Tran; Y Wong; A Mosterin; L C Katzelnick; D Labonte; T T Le; G van der Net; E Skepner; C A Russell; T D Kaplan; G F Rimmelzwaan; N Masurel; J C de Jong; A Palache; W E P Beyer; Q M Le; T H Nguyen; H F L Wertheim; A C Hurt; A D M E Osterhaus; I G Barr; R A M Fouchier; P W Horby; D J Smith
Journal:  Science       Date:  2014-11-21       Impact factor: 47.728

10.  Neutralizing antibodies after infection with dengue 1 virus.

Authors:  Maria G Guzman; Mayling Alvarez; Rosmari Rodriguez-Roche; Lidice Bernardo; Tibaire Montes; Susana Vazquez; Luis Morier; Angel Alvarez; Ernest A Gould; Gustavo Kouri; Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more
  90 in total

1.  Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Authors:  Leah C Katzelnick; Magelda Montoya; Lionel Gresh; Angel Balmaseda; Eva Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

3.  Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Authors:  Kimberly A Dowd; Christina R DeMaso; Rebecca S Pelc; Scott D Speer; Alexander R Y Smith; Leslie Goo; Derek J Platt; John R Mascola; Barney S Graham; Mark J Mulligan; Michael S Diamond; Julie E Ledgerwood; Theodore C Pierson
Journal:  Cell Rep       Date:  2016-07-29       Impact factor: 9.423

Review 4.  Dengue: knowledge gaps, unmet needs, and research priorities.

Authors:  Leah C Katzelnick; Josefina Coloma; Eva Harris
Journal:  Lancet Infect Dis       Date:  2017-02-07       Impact factor: 25.071

Review 5.  The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.

Authors:  Leah C Katzelnick; Eva Harris
Journal:  Curr Opin Virol       Date:  2018-03-26       Impact factor: 7.090

6.  Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.

Authors:  Awadalkareem Adam; Marcia Woda; Sonia Kounlavouth; Alan L Rothman; Richard G Jarman; Josephine H Cox; Julie E Ledgerwood; Gregory D Gromowski; Jeffrey R Currier; Heather Friberg; Anuja Mathew
Journal:  J Immunol       Date:  2018-11-09       Impact factor: 5.422

7.  Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.

Authors:  Jesica A Swanstrom; Sandra Henein; Jessica A Plante; Boyd L Yount; Douglas G Widman; Emily N Gallichotte; Hansi J Dean; Jorge E Osorio; Charalambos D Partidos; Aravinda M de Silva; Ralph S Baric
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

8.  Rise and fall of vector infectivity during sequential strain displacements by mosquito-borne dengue virus.

Authors:  C C Andrade; K I Young; W L Johnson; M E Villa; C A Buraczyk; W B Messer; K A Hanley
Journal:  J Evol Biol       Date:  2016-08-08       Impact factor: 2.411

9.  Enhancing dengue virus maturation using a stable furin over-expressing cell line.

Authors:  Swati Mukherjee; Devika Sirohi; Kimberly A Dowd; Zhenguo Chen; Michael S Diamond; Richard J Kuhn; Theodore C Pierson
Journal:  Virology       Date:  2016-07-13       Impact factor: 3.616

10.  Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.

Authors:  Magelda Montoya; Matthew Collins; Wanwisa Dejnirattisai; Leah C Katzelnick; Henry Puerta-Guardo; Ramesh Jadi; Samuel Schildhauer; Piyada Supasa; Sirijitt Vasanawathana; Prida Malasit; Juthathip Mongkolsapaya; Aruna D de Silva; Hasitha Tissera; Angel Balmaseda; Gavin Screaton; Aravinda M de Silva; Eva Harris
Journal:  J Infect Dis       Date:  2018-07-13       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.